Comparison the intraoperative outcomes of intrauterine instillation of E-Aminocaproeic Acid and intravenous oxytocin in hysteroscopy surgeries

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201409235283N10

Enrollment

144

Registered

2014-10-14

Start date

2014-10-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Polyp of corpus uteri. Condition 2: endometrial tickness. Condition 3: Submucous leiomyoma. Polyp of corpus uteri Endometrial glandular hyperplasia Submucous leiomyoma of uterus

Interventions

Intervention 1: Group B: placebo i.e., dextrose 5% in the same form inside one liter of the dextrose 5%. Intervention 2: Group A: E-Aminocaproeic Acid in dextrose 5% inside one liter of the dextrose 5

Placebo

Treatment - Drugs

Group B: placebo i.e., dextrose 5% in the same form inside one liter of the dextrose 5%

Group A: E-Aminocaproeic Acid in dextrose 5% inside one liter of the dextrose 5%

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: history of persistent uterine bleeding accompanied with endometrial thickness, endometrial polyp or submucous myoma less than 5 cm in diameters and patients' willing to participate Exclusion criteria: Patients with the history of cardiopulmonary and liver disease, hypertension, diabetes, hyperlipidemia, cervical and uterine cancers, submucous myomas more than 5 cm in diameters

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Interaoperative bleeding. Timepoint: at the end of surgery. Method of measurement: Visual scale.;Duration of surgery. Timepoint: from the beginning to the end of surgery. Method of measurement: Questionnaire.;Volume of injected media. Timepoint: after finishing of every one litre serum. Method of measurement: number of injected serums.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: continious. Method of measurement: monitor.;Bradycardia. Timepoint: continious. Method of measurement: monitor.;Gastrointestinal side effects. Timepoint: every 1 hour. Method of measurement: clinical signs and symptoms.;Headache. Timepoint: every 1 hours. Method of measurement: clinical symptoms.;Post operative bleeding. Timepoint: every 15 minuts. Method of measurement: clinical signs and symptoms.;Duration of hospital stay. Timepoint: From admission to discharge. Method of measurement: Questionnaire.	—

Measure

Time frame

Blood pressure. Timepoint: continious. Method of measurement: monitor.;Bradycardia. Timepoint: continious. Method of measurement: monitor.;Gastrointestinal side effects. Timepoint: every 1 hour. Method of measurement: clinical signs and symptoms.;Headache. Timepoint: every 1 hours. Method of measurement: clinical symptoms.;Post operative bleeding. Timepoint: every 15 minuts. Method of measurement: clinical signs and symptoms.;Duration of hospital stay. Timepoint: From admission to discharge. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Manizhe Sayyah-Melli

Tabriz University Of Medical Sciences

wrhrcenter@gmail.com;lahroudin@gmail.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026